Profusa (PFSA) Net Income towards Common Stockholders (2022 - 2026)
Profusa's (PFSA) quarterly Net Income towards Common Stockholders came in at -$4.6 million in Q1 2026, down 311.28% year-on-year from $2.2 million in Q1 2025, and up 0.9% quarter-over-quarter from -$4.6 million in Q4 2025.
Profusa (PFSA) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Profusa's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$4.6 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 311.28% year-over-year to -$4.6 million in Q1 2026; TTM through Mar 2026 was -$40.0 million, a 343.98% decrease from a year earlier, with the FY2025 full-year figure at -$70.7 million, down 711.45% from the prior year.
- Net Income towards Common Stockholders climbed to -$4.6 million in Q1 2026 per PFSA's latest filing, from -$4.6 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $1.4 million in Q3 2022 and bottomed at -$22.6 million in Q3 2025.
- The 5-year median for Net Income towards Common Stockholders is -$397487.0 (2024), against an average of -$2.8 million.
- Across the five-year window, Net Income towards Common Stockholders soared 129.48% in 2024 and slumped 24839.79% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$902046.0 in 2022, then soared by 123.58% to $212692.0 in 2023, then sank by 3666.2% to -$7.6 million in 2024, then jumped by 38.72% to -$4.6 million in 2025, then increased by 0.9% to -$4.6 million in 2026.
- Per Business Quant, the three latest PFSA Net Income towards Common Stockholders figures stand at -$4.6 million (Q1 2026), -$4.6 million (Q4 2025), and -$22.6 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.95 Bn | 176.66 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.80 Bn | 125.92 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.82 Bn | 99.60 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.54 Bn | 67.08 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.37 Bn | 44.70 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.41 Bn | 27.30 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 28.33 Bn | 26.04 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.96 Bn | 26.38 Bn | - | - |
| 9 | Koninklijke Philips | 25.43 Bn | 22.31 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Profusa | 67,213.39 | -307,786.61 | - | -4.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.61 Mn |
| Dec 31, 2025 | -4.65 Mn |
| Sep 30, 2025 | -22.56 Mn |
| Jun 30, 2025 | -8.20 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Dec 31, 2024 | -7.59 Mn |
| Sep 30, 2024 | 91,177.00 |
| Jun 30, 2024 | -397,487.00 |
| Mar 31, 2024 | -820,277.00 |
| Dec 31, 2023 | 212,692.00 |
| Sep 30, 2023 | -309,328.00 |
| Jun 30, 2023 | 134,623.00 |
| Mar 31, 2023 | 336,660.00 |
| Dec 31, 2022 | -902,046.00 |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 260,531.00 |
| Mar 31, 2022 | 797,050.00 |